Article PDF
References
Qiu C, Winblad B, Fratiglioni L : The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487–499.
Wright JW, Reichert JR, Davis CJ, Harding JW : Neural plasticity and the brain renin-angiotensin system. Neurosci Biobehav Rev 2002; 26: 529–552.
Takeda S, Sato N, Ogihara T, Morishita R : The renin-angiotensin system, hypertension and cognitive dysfunction in Alzheimer's disease: new therapeutic potential. Front Biosci 2008; 13: 2253–2265.
Gard PR, Rusted JM : Angiotensin and Alzheimer's disease: therapeutic prospects. Expert Rev Neurother 2004; 4: 87–96.
Gasparo MD, Catt KJ, Inagami T, Wright JW, Unger TH : International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharm Rev 2000; 52: 415–472.
Viswanathan M, Tsutsumi K, Correa FJ, Saavedra JM : Changes in expression of angiotensin receptor subtypes in the rat aorta during development. Biochem Biophys Res Commun 1991; 179: 1361–1367.
Näveri L : The role of angiotensin receptor subtypes in cerebrovascular regulation in the rat. Acta Physiol Scand 1995; 155: 2–48.
Strömberg C, Näveri L, Saavedra JM : Nonpeptide angiotensin AT1 and AT2 receptor ligands modulate the upper limit of cerebral blood flow autoregulation in rats. J Cereb Blood Flow Metab 1993; 13: 298–303.
Phillips MI : Functions of angiotensin in the central nervous system. Annu Rev Physiol 1987; 49: 413–435.
Landas S, Phillips MI, Stamler JF, Raizada MK : Visualization of specific angiotensin II binding sites in the brain by fluorescent microscopy. Science 1980; 210: 791–793.
Van Houten M, Schiffrin EL, Mann JF, Posner BJ, Boucher R : Radioautographic localization of specific binding sites for bloodborne angiotensin II in the rat brain. Brain Res 1980; 186: 480–485.
Iwai M, Inaba S, Tomono Y, et al : Attenuation of focal brain ischemia by telmisartan, an angiotensin type 1 receptor blocker, in atherosclerotic apolipoprotein E−deficient mice. Hypertens Res 2008; 31: 161–168.
Dahlöf B, Devereux RB, Kjeldsen SE, et al, LIFE Study Group : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Schrader J, Lüders S, Kulschewski A, et al, Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group : The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699–1703.
Mochizuki S, Dahlöf B, Shimizu M, et al, Jikei Heart Study Group : Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–1439.
Armstrong DL, Garcia EA, Ma T, Quinones B, Wayner MJ : Angiotensin II blockade of long-term potentiation at the perforant path-granule cell synapse in vitro. Peptides 1996; 17: 689–693.
Denny JB, Polan-Curtain J, Wayner MJ, Armstrong DL : Angiotensin II blocks hippocampal long-term potentiation. Brain Res 1991; 567: 321–324.
Wayner MJ, Armstrong DL, Polan-Curtain JL, Denny JB : Ethanol and diazepam inhibition of hippocampal LTP is mediated by angiotensin II and AT1 receptors. Peptides 1993; 14: 441–444.
Wayner MJ, Armstrong DL, Polan-Curtain JL, Denny JB : Role of angiotensin II and AT1 receptors in hippocampal LTP. Pharmacol Biochem Behav 1993; 45: 455–464.
Wayner MJ, Polan-Curtain JL, Armstrong DL : Dose and time dependency of angiotensin II inhibition of hippocampal long-term potentiation. Peptides 1995; 16: 1079–1082.
Morgan TM, Routtenberg A : Angiotensin injected into the neostriatum after learning disrupts retention performance. Science 1977; 196: 87–89.
Lee EH, Ma YL, Wayner MJ, Armstrong DL : Impaired retention by angiotensin II mediated by the AT1 receptor. Peptides 1995; 16: 1069.
DeNoble VJ, DeNoble KF, Spencer KR, et al : Non-peptide angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor: effect on a renin-induced deficit of a passive avoidance response in rats. Brain Res 1991; 61: 5230–5235.
Vermeer SE, Prins ND, den Heijer T, et al : Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215–1222.
Stewart R : Cardiovascular factors in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1998; 65: 143–147.
Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD : Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 1999; 354: 919–920.
de la Torre JC : Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004; 3: 184–190.
PROGRESS Collaborative Group : Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003; 163: 1069–1075.
Lithell H, Hansson L, Skoog I, SCOPE Study Group : The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens 2004; 8: 1605–1612.
Trenkwalder P : The Study on COgnition and Prognosis in the Elderly (SCOPE)—recent analyses. J Hypertens Suppl 2006; 24: S107–S114.
Benson SC, Pershadsingh HA, Ho CI, et al : Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43: 993–1002.
Kurtz TW : Treating the metabolic syndrome: telmisartan as a peroxisome proliferator−activated receptor-gamma activator. Acta Diabetol 2005; 42 ( Suppl 1): S9–S16.
Luo Y, Yin W, Signore AP, et al : Neuroprotection against focal ischemic brain injury by the peroxisome proliferator−activated receptor-gamma agonist rosiglitazone. J Neurochem 2006; 97: 435–448.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morishita, R. Aegis against Stroke and Dementia by Angiotensin Type 1 Receptor Blockers: New Beneficial Aspects. Hypertens Res 31, 1–3 (2008). https://doi.org/10.1291/hypres.31.1
Received:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1
Keywords
This article is cited by
-
High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension
Hypertension Research (2011)